Skip to content

The Extract of Green Tea on Obese Women: a Randomized Double Blindness Clinical Trial

The Extract of Green Tea on Obese Women: a Randomized Double Blindness Clinical Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00383058
Enrollment
100
Registered
2006-10-02
Start date
2006-09-30
Completion date
2007-06-30
Last updated
2009-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

obesity, green tea

Brief summary

The purpose of this study is to examine whether the extract of the green tea is effective on obese women.

Detailed description

We conducted the pilot study in 2005. The initial findings showed the extract of green tea is benefit on obese women. The potential benefit include appetite lowing, lipid markers decreasing and regulating balance of obese related hormone peptides. So we designed this trial.

Interventions

DRUGthe extract of green tea

Sponsors

National Science and Technology Council, Taiwan
CollaboratorOTHER_GOV
Taipei Hospital, Taiwan
CollaboratorOTHER
Taipei City Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
FEMALE
Age
16 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

1. Age 16-60 years old female 2. BMI\>27㎞/m2 3. Signed informed consent

Exclusion criteria

1. Endocrine disease, e.g. thyroid disorder, pituitary disorder, and sex gland disorder. 2. Heart disease, e.g. arrhythmia, heart failure, myocardial infarction, and patient with pacemaker. 3. Allergy and Immunology disease. 4. High aminotransferases ( Alanine, Aspartate \>80 IU/L) or high serum Creatinine (\>2.5 mg/dL) 5. Pregnant or lactating women. 6. Childbirth within 6 months. 7. Stroke or otherwise unable to exercise 8. Management for weight control within 3 months. 9. Any other conditions deemed unsuitable for trial as evaluated by the physician-in-charge.

Design outcomes

Primary

MeasureTime frame
(Percent) reduction of body mass index and body weight

Secondary

MeasureTime frame
(Percent) reduction of: Glucose, cholesterol,LDL, HDL and triglyceride
leptin, adiponectin and ghrelin comparisons and analysis

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026